Showing results (31-40 of 81) with videos related to
Sort By:
Pageof 9
British Journal of Haematology|July 24, 2015
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II studyPeter M Voorhees, Robert Z Orlowski, Flora Mulkey, et al.Blood Cancer Journal|May 28, 2024
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparitiesSikander Ailawadhi, Yaw Adu, Ryan D Frank, et al.Cancer Medicine|August 17, 2023
The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancersSikander Ailawadhi, Meghna Ailawadhi, Navnita Dutta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2007
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemiaSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.Leukemia & Lymphoma|June 1, 2013
Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cellsKasyapa S Chitta, A Nazmul H Khan, Noreen Ersing, et al.Cancer|October 29, 2009
Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myelomaSikander Ailawadhi, Ahmed N Abdelhalim, Lyudmyla Derby, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.Blood|March 25, 2016
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Paul G Richardson, Todd M Zimmerman, Craig C Hofmeister, et al.British Journal of Haematology|October 21, 2011
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour responseAsher A Chanan-Khan, Kasyapa Chitta, Noreen Ersing, et al.Journal of Oncology Practice|March 26, 2015
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levelsTait D Shanafelt, Bijan J Borah, Heidi D Finnes, et al.Pageof 9